X-Chem Acquires Glamorous AI

X-Chem Acquires Glamorous AI and ComInnex

October 29, 2021

Biotechnology

X-Chem, a GHO Capital-backed leader in DNA-encoded library (DEL) technology, has acquired AI drug-discovery specialist Glamorous AI and Budapest-based synthetic chemistry services provider ComInnex. The deals expand X-Chem’s machine-learning capabilities and synthetic chemistry capacity, broadening its global footprint and accelerating small-molecule discovery services for biopharma clients.

GHO Capital Acquires X‑Chem, Inc.

June 3, 2020

Biotechnology

GHO Capital Partners LLP has acquired X‑Chem, Inc., the Waltham-based provider of DNA‑Encoded Library (DEL) small‑molecule discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman. GHO will invest in X‑Chem's DEL platform and support international growth while appointing co‑founder Matt Clark as CEO.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

Marvell Technology Acquires Celestial AI

February 2, 2026

AI & Machine Learning

Marvell Technology, Inc. completed its acquisition of Celestial AI, bringing Celestial’s Photonic Fabric optical interconnect technology into Marvell’s Data Center Group to strengthen its AI and data center connectivity capabilities. Marvell expects initial revenue contributions beginning in the second half of fiscal 2028, with material ramp to a $500 million annualized run rate by Q4 FY2028 and $1 billion by Q4 FY2029; the deal reduced Marvell’s cash balance by $1 billion and added roughly $50 million in annual non-GAAP operating expenses.

AstraZeneca Acquires Modella AI

January 15, 2026

AI & Machine Learning

AstraZeneca has acquired Modella AI, a Boston-based biomedical AI company, to integrate its multimodal foundation models and agentic AI platform into AstraZeneca's global oncology R&D organization. The deal expands an existing multi-year collaboration to accelerate clinical development, improve biomarker discovery, and drive data-driven decision-making across AstraZeneca's oncology pipeline; financial terms were not disclosed.

SpaceX Acquires xAI

February 2, 2026

AI & Machine Learning

SpaceX has acquired xAI in a transaction reported to value the combined company at about $1.25 trillion. The deal is described as a vertical integration to combine SpaceX’s launch and satellite infrastructure with xAI’s AI model development capabilities, including ambitions for space-based data centers and orbital compute.